After everolimus resistance, it is usually to switch to other targeted drugs, or use systemic chemotherapy anti-tumor, or choose immune drug therapy, etc..
Everolimus is an antitumor drug that acts on the mTOR pathway in the human body, and is currently used in clinical practice as a third-line treatment for patients with advanced renal cell carcinoma, advanced neuroendocrine tumors, and renal vascular smooth muscle lipoma associated with tuberous sclerosis.
Taking renal cancer as an example, if drug resistance develops with everolimus, the treatment can be continued in the following ways.
1. Re-do the second generation gene sequencing for the patient, and according to the type of gene mutation found, choose the targeted targeted drug for treatment.
2. For patients whose genetic testing does not reveal any mutated genes, targeted drugs combined with immune drugs are generally considered.
3. Patients with high expression of PDL1 immunity detected by post-drug resistance examination can choose immune drug therapy, such as PD1 antibody and ibritumomab.